Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Weber

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
AIDS (London, England)|August 23, 2018
Aging and the evolution of comorbidities among HIV-positive individuals in a European cohortAnnegret Pelchen-Matthews, Lene Ryom, Álvaro H Borges, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European CohortAnnegret Pelchen-Matthews, Álvaro H Borges, Joanne Reekie, et al.
Circulation. Cardiovascular Interventions|August 15, 2025
Procedural and Clinical Outcomes After Orbital Atherectomy Versus Intravascular Lithotripsy in Patients With Calcified NodulesAli H Dakroub, Doosup Shin, Mandeep Singh, et al.
Plos One|May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I TrialAgricola Joachim, Asli Bauer, Sarah Joseph, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Plos One|November 30, 2018
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial designEdna O Viegas, Arne Kroidl, Patricia J Munseri, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 6, 2025
Photon-counting detector computed tomography for the assessment of coronary stents and in-stent restenosisDoosup Shin, Rick H J A Volleberg, Roosha Parikh, et al.
Frontiers in Immunology|May 21, 2019
Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|August 23, 2018
Aging and the evolution of comorbidities among HIV-positive individuals in a European cohortAnnegret Pelchen-Matthews, Lene Ryom, Álvaro H Borges, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European CohortAnnegret Pelchen-Matthews, Álvaro H Borges, Joanne Reekie, et al.
Circulation. Cardiovascular Interventions|August 15, 2025
Procedural and Clinical Outcomes After Orbital Atherectomy Versus Intravascular Lithotripsy in Patients With Calcified NodulesAli H Dakroub, Doosup Shin, Mandeep Singh, et al.
Plos One|May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I TrialAgricola Joachim, Asli Bauer, Sarah Joseph, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Plos One|November 30, 2018
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial designEdna O Viegas, Arne Kroidl, Patricia J Munseri, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 6, 2025
Photon-counting detector computed tomography for the assessment of coronary stents and in-stent restenosisDoosup Shin, Rick H J A Volleberg, Roosha Parikh, et al.
Frontiers in Immunology|May 21, 2019
Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Pageof 12